Status:
TERMINATED
Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping)
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
White Matter Hyperintensity
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Many central nervous system pathologies have an inflammatory component, often associated with an accumulation of disability and more severe tissue damage. In multiple sclerosis, the inflammatory proc...
Detailed Description
Several MRI imaging tools are known to be highly sensitive to tissue iron content and have become the method of choice to study brain iron, including in a pathological context such as multiple scleros...
Eligibility Criteria
Inclusion
- Subject over 18 years old
- Consent to participate in the study
- Beneficiary of a social protection scheme
- Healthy volunteers: Consent to be informed if an unexpected anomaly is revealed by the imagery.
- Patients: With MS defined according to McDonald's revised criteria for spatial dissemination and temporal or clinical or radiological temporal dissemination and who should benefit from MRI in the imaging department
Exclusion
- Absolute contraindication to 3T MRI
- Realization of an injected MRI (gadolinium) in the previous year
- Patient benefiting from a legal protection measure
- Pregnant or breastfeeding woman
- For healthy volunteers: History of neurological pathology or neurological pathology in progress
Key Trial Info
Start Date :
December 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 16 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04465448
Start Date
December 17 2020
End Date
June 16 2022
Last Update
December 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hhopital fondation adolphe de rothschild
Paris, France, 75019